Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma

[1]  John A. Calarco,et al.  Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma , 2019, Nature.

[2]  John A. Calarco,et al.  Recurrent non-coding U1-snRNA mutations drive cryptic splicing in Shh medulloblastoma , 2019, Nature.

[3]  W. J. Valente,et al.  Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA , 2018, Nature Communications.

[4]  Reporting for specific materials, systems and methods , 2018 .

[5]  Nir Hacohen,et al.  Resistance to checkpoint blockade therapy through inactivation of antigen presentation , 2017, Nature Communications.

[6]  Yvan Saeys,et al.  ConTra v3: a tool to identify transcription factor binding sites across species, update 2017 , 2017, Nucleic Acids Res..

[7]  E. V. Van Allen,et al.  Genomic Approaches to Understanding Response and Resistance to Immunotherapy , 2016, Clinical Cancer Research.

[8]  Y. Saeys,et al.  ConTra v3: a tool to identify transcription factor binding sites across species, update 2016 , 2016 .

[9]  A. Mottok,et al.  Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion , 2016, The Journal of experimental medicine.

[10]  J. Olson,et al.  HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. , 2016, Cancer cell.

[11]  Tania L. Slatter,et al.  Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12 , 2016, Oncoimmunology.

[12]  Gary D. Bader,et al.  Divergent clonal selection dominates medulloblastoma at recurrence , 2016, Nature.

[13]  G. Calin,et al.  PDL1 Regulation by p53 via miR-34 , 2015, Journal of the National Cancer Institute.

[14]  P. Acton,et al.  Peripheral Administration of Tumor Necrosis Factor-Alpha Induces Neuroinflammation and Sickness but Not Depressive-Like Behavior in Mice , 2015, BioMed research international.

[15]  M. Wiesmann,et al.  Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097 , 2015, Molecular Cancer Therapeutics.

[16]  Michel Sadelain,et al.  The journey from discoveries in fundamental immunology to cancer immunotherapy. , 2015, Cancer cell.

[17]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[18]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[19]  X. Chen,et al.  Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. , 2015, Cellular signalling.

[20]  Florence I. Raynaud,et al.  Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease , 2015, Cancer cell.

[21]  D. Corcoran,et al.  Pax3 expression enhances PDGF-B-induced brainstem gliomagenesis and characterizes a subset of brainstem glioma , 2014, Acta neuropathologica communications.

[22]  Gary D Bader,et al.  Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma , 2014, Nature.

[23]  T. Lagerweij,et al.  Human pontine glioma cells can induce murine tumors , 2014, Acta Neuropathologica.

[24]  Bei Wang,et al.  p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1 , 2013, Nature Communications.

[25]  F. Dammacco,et al.  MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. , 2013, Journal of the National Cancer Institute.

[26]  B. Garcia,et al.  Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma , 2013, Science.

[27]  Stefan M. Pfister,et al.  HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment , 2012, Journal of Neuro-Oncology.

[28]  M. Prados,et al.  Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment , 2012, Journal of Neuro-Oncology.

[29]  P. Febbo,et al.  An animal model of MYC-driven medulloblastoma. , 2012, Cancer cell.

[30]  David E. Anderson,et al.  Medulloblasoma: challenges for effective immunotherapy , 2012, Journal of Neuro-Oncology.

[31]  M. Konopleva,et al.  p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12. , 2011, Blood.

[32]  L. Diaz,et al.  Systemic use of tumor necrosis factor alpha as an anticancer agent , 2011, Oncotarget.

[33]  F. Pazos,et al.  Genetic polymorphisms among C57BL/6 mouse inbred strains , 2011, Transgenic Research.

[34]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[35]  M. Shago,et al.  Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  T. Lawrence.  The nuclear factor NF-kappaB pathway in inflammation. , 2009, Cold Spring Harbor perspectives in biology.

[37]  T. Ichisaka,et al.  Suppression of induced pluripotent stem cell generation by the p53–p21 pathway , 2009, Nature.

[38]  Robert Machold,et al.  Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. , 2008, Cancer cell.

[39]  Nihal Ahmad,et al.  Dose translation from animal to human studies revisited , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  D. Grochová,et al.  Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124. , 2005, Oncology reports.

[41]  C. Benedict,et al.  A Lymphotoxin-IFN-β Axis Essential for Lymphocyte Survival Revealed during Cytomegalovirus Infection1 , 2005, The Journal of Immunology.

[42]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[43]  M. Gore,et al.  Interferon‐alpha (IFN‐α) stimulates anti‐melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC) , 2000, Clinical and experimental immunology.

[44]  Xinbin Chen,et al.  p53 induces TAP1 and enhances the transport of MHC class I peptides , 1999, Oncogene.

[45]  K. Pfeffer,et al.  The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. , 1998, Immunity.

[46]  H. Neumann,et al.  Major Histocompatibility Complex (MHC) Class I Gene Expression in Single Neurons of the Central Nervous System: Differential Regulation by Interferon (IFN)-γ and Tumor Necrosis Factor (TNF)-α , 1997, The Journal of experimental medicine.

[47]  T. Bowman,et al.  Tissue-specific inactivation of p53 tumor suppression in the mouse. , 1996, Genes & development.

[48]  G. Reaman,et al.  Phase I Study of Tumor Necrosis Factor-α and Actinomycin D in Pediatric Patients with Cancer: A Children's Cancer Group Study , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[49]  W. Furman,et al.  Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: a Pediatric Oncology Group study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  R. Holmdahl,et al.  Placental MHC class I antigen expression is induced in mice following in vivo treatment with recombinant interferon-gamma. , 1991, Journal of reproductive immunology.

[51]  M. Ciancio,et al.  Comparative and interactive in vivo effects of tumor necrosis factor alpha and endotoxin. , 1991, Circulatory shock.

[52]  C. Ware,et al.  Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin (LT) on human T lymphocytes. TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4+ T cell hybridoma. , 1990, Journal of immunology.

[53]  S. Weiss,et al.  Tumor necrosis factor induces expression of MHC class I antigens on mouse astrocytes , 1988, Journal of Neuroimmunology.

[54]  J. West,et al.  Regulation of MHC Protein Expression in Pancreatic β-Cells by Interferon-γ and Tumor Necrosis Factor-α , 1988 .

[55]  Shigeru Tsuchiya,et al.  Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1) , 1980, International journal of cancer.

[56]  K. Nilsson,et al.  Establishment and characterization of a human histiocytic lymphoma cell line (U‐937) , 1976, International journal of cancer.